Inclusion Criteria:

- Female patients, age ≦65 years

- Biopsy proven lymph node positive, estrogen receptor- positive primary breast cancer

- Must have completed a 4-cycle neo-adjuvant chemotherapy with a standard
regimen(containing anthracycline or paclitaxel)

- Must have undergone surgery to remove the primary tumor by either a mastectomy or
enlarged local excision

- Postoperative residual positive lymph nodes or G1/G2/G3 of Miller & Payne Grading
System

- Adequate recovery from recent surgery

- No history of other malignancies

- No currently uncontrolled diseased or active infection

- Not pregnant or breast feeding, and on appropriate birth control if of child-bearing
potential

- Adequate cardiovascular function reserve with a myocardial infarction within the past
six month

- Adequate hematologic function with:

1. Absolute neutrophil count (ANC) ≥1500/mm3

2. Platelets ≥100,000/ mm3

3. Hemoglobin ≥10 g/dL

- Adequate hepatic and renal function with:

1. Serum bilirubin ≤1.5×UNL

2. Alkaline phosphatase and alanine aminotransferase (ALT) ≤2.5 x ULN. (≤5 x ULN is
acceptable in the setting of hepatic metastasis)

3. BUN between 1.7 and 8.3 mmol/L

4. Cr between 40 and 110 umol/L

- Knowledge of the investigational nature of the study and Ability to give informed
consent

- Ability and willingness to comply with study procedures.

Exclusion Criteria:

- Known or suspected distant metastases

- Concurrent malignancy or history of other malignancy

- Uncontrolled diseases(e.g., heart failure, myocardial infarction within 6 months,
arrhythmia, unstable diabetes, hypercalcemia) or active infection

- Geographical, social, or psychological problems that would compromise study
compliance

- Known or suspected hypersensitivity to anthracycline or paclitaxel